Silver Book Fact

Donepezil, a new Alzheimer’s medication, increased prescription costs to $1,000 per patient, however the overall health care costs decreased from $11,947 to $8,056.

Hill, Jerrold W., Robert Futterman, Vera Mastey, and Howard Fillit. The Effect of Donepezil Therapy on Health Costs in a Medicare Managed Care Plan. Managed Care Interface. 2002; 15(3): 63-70. http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=Retrieve&db=PubMed&list_uids=11925682&dopt=AbstractPlus

Reference

Title
The Effect of Donepezil Therapy on Health Costs in a Medicare Managed Care Plan
Publication
Managed Care Interface
Publication Date
2002
Authors
Hill, Jerrold W., Robert Futterman, Vera Mastey, and Howard Fillit
Volume & Issue
Volume 15, Issue 3
Pages
63-70
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • A medicine is in development that aims to prevent or reverse Alzheimer’s disease progression by using a human monoclonal antibody specifically designed to remove beta amyloid protein from the brain.  
  • Out-of-Pocket Costs, 5-Year Delayed Onset  
  • According to the Pharmaceutical Research and Manufacturers of America, because of medical research, the number of Americans with Alzheimer’s could decrease by 3 million in 2025.  
  • Use of existing or new drugs/compounds for Alzheimer’s prevention could result in a delay of onset of between 2 and 5 years.  
  • An Alzheimer’s disease treatment breakthrough that slowed its progression and began to show its effects in 2015, would reduce the Medicare costs for people with the disease by $20 billion…